3 days ago
Leerink Partners Remains a Hold on Quanterix (QTRX)
Leerink Partners analyst Puneet Souda maintained a Hold rating on Quanterix (QTRX – Research Report) on June 2. The company's shares closed yesterday at $5.58.
Confident Investing Starts Here:
Souda covers the Healthcare sector, focusing on stocks such as Quanterix, Bruker, and Guardant Health. According to TipRanks, Souda has an average return of -12.3% and a 29.46% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quanterix with a $12.33 average price target.
Based on Quanterix's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $30.33 million and a GAAP net loss of $20.5 million. In comparison, last year the company earned a revenue of $32.07 million and had a GAAP net loss of $10.07 million
